Diagnosis of Arrhythmias in Syncope by Pocket-ECG III® or Conventional Holter (SINPocket)

July 16, 2017 updated by: Ignacio Mosquera, Complexo Hospitalario Universitario de A Coruña

Diagnosis of Arrhythmias in Patients With Syncope by Continuous Cardiac Telemetry (Pocket-ECG III® System) or Conventional Holter

The purpose of this study is to determine whether continuous cardiac telemetry with the Pocket-ECG III® system is more useful than conventional Holter to find out the cause of syncope

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Study population: adult patients with recurrent and/or with probable cardiac origin syncopes with indication of cardiac rhythm monitoring.

Estimated sample size: COLAPS trial showed that conventional 48-hours Holter and 4-weeks external loop recorder got a diagnosis in 22% and 56%, respectively, in patients with syncope. Based on this data, to compare two matched-proportions with α-risk=0.05 and β-risk=0.2, 34 patients would be needed; to compensate a 15-20% percentage of lost patients during follow-up, it is estimated that 40 patients is the number to include in the trial to demonstrate the effect.

Variables to collect:

Baseline variables: birthdate date (month, year), inclusion date, gender, number and features of syncopes, cardiovascular risk factors, electrocardiogram, type of cardiopathy, left ventricular ejection fraction, comorbidities and treatments.

Monitoring findings: diagnostic event and diagnostic fulfilled criteria, date of diagnostic event, date of last follow-up.

Safety and adverse events: monitoring length, unexpected battery depletion, number of losses of mobile phone signal, cutaneous reactions to electrodes.

Costs: the costs of every diagnostic procedure used from inclusion to the end of follow-up will be added, based on prespecified costs of every item (Decreto 56/2014 of the Consellería de Sanidade de la Xunta de Galicia, which specifies the costs of every diagnostic or therapeutic intervention in centers depending on the Servicio Gallego de Salud).

Intervention description: patients with indication of conventional Holter monitoring will be consecutively included. After signing written informed consent, a Pocket-ECG III® system will be given to the patient. All participants will be monitored by the Pocket-ECG III® system until a diagnosis is achieved or for a maximum of two months (whatever it happens first). Everyday daily reports sent via e-mail by the manufacturer company (MEDICALgorithmics© S.A.) will be reviewed by the investigator team; in case of a diagnosis event (according to prespecified diagnostic criteria from the European Society of Cardiology), appropriate treatment will be applied.

Every patient will be his/her own control. Conventional 24-hours Holter monitoring will be simulated using data obtained by the Pocket-ECG III® system in the first 24 hours, ignoring the registries of the rest of days. Two and Three 24-hours conventional Holter strategies will also be simulated analyzing data from first 24 hours and 1-2 additional days, respectively, chosen by means of a random number creation system which will identify the days of registry to be considered. Diagnostic criteria in this virtual control group will be the same as used in the actual Pocket-ECG III® system monitoring group.

Follow-up: patients will be followed-up by two complementary manners

  1. Real-time remote: Pocket-ECG III® system sends continuously the registered electrocardiogram sinal via GSM mobile phone to a central unit sited in Poland, where the signal is processed and interpreted. From this central unit, a daily report and a weekly summary report is sent by e-mail to the investigator team. If a lost in the mobile phone coverage happens, the system stores the registry in its memory until the coverage is recovered, when the whole stored registry is sent.
  2. Purpose-created outpatient clinic.

Statistical methods: categorical variables will be expressed as "absolute number (percentage)" and continuous variables as "mean ± standard deviation", adding "median (interquartile range)" when the distribution of values is far from normal distribution assessed by Kolmogorov-Smirnov and Shapiro-Wilk methods. Proportion of diagnosis achieved by each strategy will be compared by McNemar for intrasubject measures or binomial exact methods, whichever applies. Economic burden of each strategy will be compared with the t-Student for intrasubject measures or T de Wilcoxon methods, whichever applies. All tests of significance will be 2-sided, with p<0.05 considered statistically significant. The analysis will be conducted using PASW Statistics version 18.0 (IBM, Armonk, New York) and EPIDAT 3.1 (provided by the Direccion Xeral de Saude Publica de la Consellería de Sanidade de la Xunta de Galicia).

Study Type

Interventional

Enrollment (Actual)

40

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • A Coruna, Spain, 15006
        • Complexo Hospitalario Universitario de A Coruña

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with syncope refered to perform 24-hours conventional Holter who fulfill at least one of the following conditions:

    1. ≥2 episodes of syncope in the last year, provided that they are not typical vasovagal syncope, and/or
    2. ≥1 episode of syncope with any criterion of suspicion of cardiac-arrhythmic aetiology, according to current European Guidelines about management of syncope

Exclusion Criteria:

  • Carrier of any cardiac implantable electronic device or internal loop recorder, as well as stablished indication for it according to current guidelines.
  • Aetiologic diagnosis of syncope already known.
  • Left ventricular ejection fraction ≤35%.
  • Unability to perform the monitorization

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Pocket-ECG III System
After signing written informed consent, a Pocket-ECG III® system will be given to the patient. All participants will be monitored by the Pocket-ECG® system until a diagnosis is achieved or for a maximum of two months (whatever it happens first). Everyday daily reports sent via e-mail by the manufacturer company (MEDICALgorithmics© S.A.) will be reviewed by the investigator team; in case of a diagnosis event (according to prespecified diagnostic criteria from the European Society of Cardiology), appropriate treatment will be applied.
Continuous cardiac telemetry until diagnosis or a maximum of two months
Active Comparator: Conventional Holter
Every patient will be his/her own control. Conventional 24-hours Holter monitoring will be simulated using data obtained by the Pocket-ECG III® system in the first 24 hours, ignoring the registries of the rest of days. Two and Three 24-hours conventional Holter strategies will also be simulated analyzing data from first 24 hours and 1-2 additional days, respectively, chosen by means of a random number creation system which will identify the days of registry to be considered.
Continuous cardiac telemetry until diagnosis or a maximum of two months

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
number of etiology diagnosis of syncope
Time Frame: two months
two months
length of time until diagnosis
Time Frame: two months
two months
Overall and per diagnosis costs
Time Frame: Two months
Two months

Secondary Outcome Measures

Outcome Measure
Time Frame
length of properly analyzable registry
Time Frame: two months
two months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ignacio Mosquera, MD, Complexo Hospitalario Universitario A Coruña

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2016

Primary Completion (Actual)

June 1, 2017

Study Completion (Actual)

June 1, 2017

Study Registration Dates

First Submitted

November 23, 2015

First Submitted That Met QC Criteria

November 23, 2015

First Posted (Estimate)

November 25, 2015

Study Record Updates

Last Update Posted (Actual)

July 19, 2017

Last Update Submitted That Met QC Criteria

July 16, 2017

Last Verified

July 1, 2017

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Syncope

Clinical Trials on Pocket-ECG III system

3
Subscribe